Abstract:Background Persons with diabetes are at risk for developing a cardiomyopathy through several pathophysiological mechanisms independent of traditional risk factors for heart failure. Among those with so-called diabetic cardiomyopathy (DbCM), the relationship between natriuretic peptides, cardiac structural abnormalities and functional capacity is largely unknown. Purpose This study aimed to evaluate associations between NT-proBNP concentrations, clinical characteristics, echocardiographic findings, health status and activity, and outcomes from cardiopulmonary exercise testing Methods The Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) trial is evaluating the effects of AT-001, a novel aldose-reductase inhibitor in participants with DbCM without a prior history of heart failure (1). Participants were included if they had a known diagnosis of type 2 diabetes and age ≥60 (or ≥45 with a duration of diabetes of ≥10 years or estimated glomerular filtration rate ≤60 mL/min/1.73m2). Participants were required to have evidence of one of: structural cardiac abnormality, elevated cardiac biomarkers, or impaired exercise tolerance, defined as a peak oxygen uptake (VO2) ≤75% of predicted. In this prespecified subgroup analysis of the ARISE-HF trial, 685 participants with baseline echocardiography data, laboratory investigations, and functional assessment were included. Participants were stratified by N-terminal pro-B type natriuretic peptide (NT-proBNP) quartiles, and correlation with echocardiographic and functional parameters were assessed using Spearman correlation test. Results The mean age of participants was 67.4 years and 50% were female. The mean duration of type 2 diabetes was 14.5 years with a mean hemoglobin A1c of 6.98. The median NT-proBNP was 71 (Q1, Q3: 33, 135) ng/L. No association was observed between NT-proBNP concentrations and echocardiographic parameters of either diastolic or systolic dysfunction including global longitudinal strain, left ventricular ejection fraction, left ventricular mass index, left atrial volume index, E/e', or right ventricular systolic pressure (Figure 1). In contrast, NT-proBNP was significantly correlated with components of the Kansas City Cardiomyopathy Questionnaire (P<0.001), the Physical Activity Scale in the Elderly (P=0.004), duration of cardiopulmonary exercise testing (P<0.001), peak VO 2 (P<0.001), and ratio of minute ventilation/carbon dioxide production (P=0.002; Figure 2). Conclusion Among highly selected patients with subclinical DbCM, elevated NT-proBNP concentrations are associated with worse health status, lower activity levels, and reduced functional capacity, but not with cardiac structural abnormalities. These findings suggest that regardless of cardiac structural abnormalities, biomarker concentrations reflect important deterioration in functional capacity in affected individuals.

Association between dyspnea, chest pain, nt-probnp and cardiac impairment in people with cystic fibrosis

Cardiac Structure and Function in People with Cystic Fibrosis

Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: A multinational retrospective cohort study

Corelation Between Plasma N-terminal ProBNP(NT-proBNP) and Cardiac Dysfunction

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical diabetic cardiomyopathy

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy

Practical Algorithms for Early Diagnosis of Heart Failure and Heart Stress using NT‐proBNP: A Clinical Consensus Statement from the Heart Failure Association of the ESC

Utility of cardiopulmonary exercise testing in children and adolescents with non-cystic fibrosis bronchiectasis and primary ciliary dyskinesia.

Assessment of the diagnostic value of NT-proBNP in heart failure with preserved ejection fraction

NT-proBNP in Different Patient Groups of COPD: A Systematic Review and Meta-Analysis

N-terminal Pro-B-type Natriuretic Peptide Detection for Elderly Emergency Patients with Dyspnea

Association of accompanying dyspnoea with diagnosis and outcome of patients presenting with acute chest discomfort

N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease

N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy

The cardiomyopathy of cystic fibrosis: a modern form of Keshan disease

Resting pulmonary function and artery pressure and cardiopulmonary exercise testing in chronic heart failure patients in Taiwan - a prospective observational cross-sectional study comparing healthy subjects and interstitial lung disease patients

Electrocardiographic abnormalities and NT-proBNP levels at long-term follow-up of patients with dyspnea after pulmonary embolism

Diagnostic Utility of N-Terminal-Probnp in Differentiating Acute Pulmonary Embolism from Heart Failure in Patients with Acute Dyspnea

The Relationship of Left Ventricular Function and Plasma Concentration of BNP and NT‐proBNP in Patients with Asymptomatic Diastolic Dysfunction and Diastolic Heart Failure

Proinflammatory indicators and the relevance of echocardiography in children with cystic fibrosis

Reduced NT-proBNP threshold for risk prediction in high-risk elderly with subclinical heart failure: support from cardiopulmonary exercise testing